Croma-Pharma GmbH   Report issue

For profit Phase 2 Phase 3
Founded: Leobendorf Austria (1976)
Status: No NME R&D (1976)

Organization Overview

First Clinical Trial
2012
NCT01753752
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Croma-Pharma GmbH

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 2)

Keratoconjunctivitis Sicca (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 6